Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PRO-172 in Healthy Volunteers
NCT04693429Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bepotastine in allergic conjunctivitis (AC), sponsored by Laboratorios Sophia. Primary endpoints: Incidence of Related Unexpected Adverse Events at Day 10 and Ocular Comfort Index at Day 8. Started Sep 2020; status: completed.
02
Drugs
bepotastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04693429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693429.